Japan

The hospital processes approximately 16,000 discharge summaries each year, making this a significant opportunity for efficiency gains.

The partnership merges Fujitsu Japan’s deep knowledge of the medical field and cutting-edge technologies, including artificial intelligence, with JMDC’s sophisticated prediction models derived from insurance user data.

Hetronifly is an anti-programmed cell death protein 1 (PD-1) monoclonal antibody that has already received regulatory approval in China for treating several solid tumor types.

The trial will enroll up to 105 Japanese men across 11 sites throughout the country, with the collected data intended to support a future marketing authorization submission for TLX591-Px in Japan.

These investments will focus primarily on companies developing breakthrough technologies in gastrointestinal (GI), urology, and respiratory care.

The two pharmaceutical giants originally signed the agreement in October 2025, establishing a framework centered on bispecific antibodies and ADCs.